Inventory and Supply Sample Clauses

Inventory and Supply. At Pfizer’s request and expense, Licensee shall transfer to Pfizer (or its designee) all Products, and all components and in-process inventory with respect thereto, produced or held by Licensee as of the effective date of termination with respect to the Manufacture of Products, except as necessary to perform its obligations under Section 13.5.2(c)(i). At Pfizer’s request and expense, (A) if Licensee has sublicensed to a Third Party CMO the right to Manufacture the Products, Licensee shall, to the extent permitted by the applicable sublicense agreement, promptly assign such sublicense to Pfizer; provided, however, that (A) in no event shall Licensee be required to pay any fee in order to assign any contract under this Section 13.5.2(c)(v); and (B) if Licensee has not sublicensed the right to Manufacture the Products, Licensee shall continue to Manufacture or have Manufactured the Products for a period of not less than twelve (12) months, including, at Pfizer’s request, a reasonable stock build. Pfizer shall pay to Licensee the actual cost of Manufacturing associated with inventory and Products received by Pfizer pursuant to this Section 13.5.2(c)(v), plus ten percent (10%).

Inventory and Supply. At ImmunoGen’s request and expense, Licensee shall transfer to ImmunoGen (or its designee) all Product, components and in-process inventory produced or held by Licensee with respect to the Manufacture of Products. At ImmunoGen’s request, Licensee shall continue to Manufacture or have Manufactured the Product for a period of not less than [***], including, at ImmunoGen’s request, a reasonable stock build. ImmunoGen shall pay to Licensee [***].

Inventory and Supply. 4.1 LICENSOR agrees to use its best efforts to assist LICENSEE in establishing a suitable supply source of PRODUCTS. 4.2 LICENSEE shall provide PRODUCTS to [*]. *CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR REDACTED PORTIONS 4

Inventory and Supply. At Pfizer’s request, Licensee shall transfer to Pfizer (or its designee) all Product, components and in-process inventory produced or held by Licensee with respect to the Manufacture of Products. At Pfizer’s request, if Licensee has sublicensed to a CMO to Manufacture the Product, Licensee shall promptly assign such sublicense to Pfizer, or if not, Licensee shall continue to Manufacture or have Manufactured the Product for a period of not less than [***], including, at Pfizer’s request, a reasonable stock build. Pfizer shall pay to Licensee the actual cost of manufacturing associated with inventory and Product received by Pfizer pursuant to this Section 13.4.2(c)(v).

Inventory and Supply. At Pfizer’s request, Licensee shall transfer to Pfizer (or its designee) all TL1A Antibody and Product, components and in-process inventory held by Licensee with respect to the Terminated Territory, as of such date of termination. At Pfizer’s request, if Licensee has sublicensed to a CMO to Manufacture any Products with respect to the Terminated Territory, Licensee shall promptly assign such sublicense to Pfizer, or if not, Licensee shall continue to Manufacture or have Manufactured with respect to any Products with respect to the Terminated Territory, for a period of not less than [***], including, at Pfizer’s request, a reasonable stock build. Pfizer shall pay to Licensee [***] of manufacturing associated with inventory and any TL1A Antibody or Product received by Pfizer pursuant to this Section 15.5.4(c)(v).

Inventory and Supply. At Pfizer’s request, Licensee shall transfer to Pfizer (or its designee) all Compound and Product, components and in-process inventory held by Licensee with respect to the Manufacture of Compounds and Products as of such date of termination. At Pfizer’s request and expense, if Licensee has sublicensed to a CMO to Manufacture the Compounds or Products, Licensee shall promptly assign such sublicense to Pfizer (to the extent permitted by the applicable sublicense agreement), or if not, Licensee shall continue to Manufacture or have Manufactured the Products for a period of not less than twelve (12) months, including, at Pfizer’s request, a reasonable stock build. Pfizer shall pay to Licensee the actual cost to Licensee of manufacturing associated with inventory and Compound and Product received by Pfizer pursuant to this Section 14.5.1(c)(v).

Inventory and Supply. At ImmunoGen’s request and expense, Licensee will transfer to ImmunoGen (or its designee) all Product, components and in-process inventory produced or held by Licensee with respect to the Manufacture of Products. At ImmunoGen’s request and expense, Licensee will continue to Manufacture or have Manufactured the Product for a period of not less than 18 months. ImmunoGen will pay to Licensee the actual cost plus 15% of Manufacturing associated with inventory and Product received by ImmunoGen pursuant to this Section 12.5.2(b)(v) (Inventory and Supply).

Inventory and Supply. At Licensee’s request, Pfizer shall transfer to Licensee (or its designee) all TL1A Antibody and Product, components and in-process inventory held by Pfizer with respect to the Terminated Territory, as of such date of termination, if any. At Licensee’s request, if Pfizer has licensed to a CMO to Manufacture any Products with respect to the Terminated Territory, and if Pfizer is able to do so, Pfizer shall promptly assign such license to Licensee, or if not, Pfizer shall continue to Manufacture or have Manufactured any Products with respect to the Terminated Territory, for a period of not less than [***], including, at Licensee’s request, a reasonable stock build. Licensee shall pay to Pfizer [***] of manufacturing associated with inventory and the TL1A Antibody or Product received by Licensee pursuant to this Section 15.5.2(c)(v).

Inventory and Supply. In the event that Licensee terminates this Agreement pursuant to Section 12.4, Licensee shall have the right to sell its remaining inventory of Product with respect to the Terminated Territory so long as Licensee has fully paid, and continues to pay when due, all Royalties, Milestone Payments, Change of Control Payment or Significant Transaction Payment owed to Pfizer, and Licensee is otherwise not in material breach of this Agreement.